RTI Pays $3M for Athersys Orthopedic Implant Technology

Alachua, Fla.-based RTI Biologics will pay a $3 million license fee for rights to use Athersys’ Multipotent Adult Progenitor Cell technologies for the development of biologic implants for orthopedic applications, according to a Genetic Engineering and Biotechnology News report.

Advertisement
Caitlin LeValley

RTI aims to make the first MAPC technology-based implants available for use in orthopedic surgery in early 2012.

Athersys stands to earn another $2 million in development and commercialization milestones and $35.5 million in cumulative revenue milestones, according to the report.

Read the Genetic Engineering and Biotechnology News report on the RTI, Athersy’s deal.

Read other coverage on orthopedic devices:

– Orthopedic Implant Device Can Increase Bone Length

– Top 5 Orthopedic Device Companies Based on 2009 Revenues

How Emplify Health by Gundersen Aligned Surgical Asset Spending with Long-term Growth

Recommended OnDemand Webinar

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.